Exenatide, a synthetic GLP-1 analogue, is a new antidiabetic agent from the group of incretine mimetics ciming into the daily clinical practice. In our study we evaluated the effect of 6-monaths treatment with exenatide on diabetes compensation, anthropometric and biochemical parameters in the patients with poorly controlled type 2 diabetes mellitus and obesity.